---
figid: PMC4513933__12943_2015_404_Fig2_HTML
figtitle: Summary of the interactions between the PI3K/AKT pathway and RUNX2 with
  integration of the TGFB pathway
organisms:
- NA
organisms_ner:
- Homo sapiens
pmcid: PMC4513933
filename: 12943_2015_404_Fig2_HTML.jpg
figlink: /pmc/articles/PMC4513933/figure/Fig2/
number: F2
caption: 'Summary of the interactions between the PI3K/AKT pathway and RUNX2 with
  integration of the TGFβ pathway. Some genes regulated by RUNX2 and supporting different
  aspects of tumor progression are represented. The activation of growth factor receptors,
  such as G-protein coupled receptors (GPCR), receptor tyrosine kinases (RTKs), TGFβ
  receptor, results in successive activation of PI3K and AKT. PTEN inactivation also
  results in activation of PI3K and AKT. AKT activation positively regulates RUNX2
  expression and activity by direct and indirect mechanisms as shown in Fig. . Reciprocally,
  RUNX2 activates the PI3K/AKT pathway by regulation if its components, PI3K and AKT,
  or regulation of mTOR and RICTOR, two majors components of mTORC2, which phosphorylates
  AKT on serine 473. Upon receptor activation, the kinases ERK and p38 also phosphorylate
  and activate RUNX2. Through partnering with SMADs transcription factors, RUNX2,
  (TGFβ target gene itself) activates the expression of genes involved in EMT, invasion
  and the metastatic cascade, angiogenesis and bone disease. OPN: osteopontin; BSP:
  Bone sialoprotein; MMP: Matrix metalloproteinase; FAK: Focal adhesion kinase; IHH:
  Indian hedgehog; PTHrP: Parathyroid hormone-related protein; VEGF: Vascular endothelial
  growth factor; IL8: Interleukin-8. IL11: Interleukin-11; PAI-1: Plasminogen activator
  inhibitor-1'
papertitle: RUNX2 and the PI3K/AKT axis reciprocal activation as a driving force for
  tumor progression.
reftext: Karine A. Cohen-Solal, et al. Mol Cancer. 2015;14:137.
year: '2015'
doi: .na.character
journal_title: .na.character
journal_nlm_ta: .na.character
publisher_name: .na.character
keywords: .na.character
automl_pathway: 0.8967273
figid_alias: PMC4513933__F2
figtype: Figure
redirect_from: /figures/PMC4513933__F2
ndex: cdcc6e44-def2-11ea-99da-0ac135e8bacf
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC4513933__12943_2015_404_Fig2_HTML.html
  '@type': Dataset
  description: 'Summary of the interactions between the PI3K/AKT pathway and RUNX2
    with integration of the TGFβ pathway. Some genes regulated by RUNX2 and supporting
    different aspects of tumor progression are represented. The activation of growth
    factor receptors, such as G-protein coupled receptors (GPCR), receptor tyrosine
    kinases (RTKs), TGFβ receptor, results in successive activation of PI3K and AKT.
    PTEN inactivation also results in activation of PI3K and AKT. AKT activation positively
    regulates RUNX2 expression and activity by direct and indirect mechanisms as shown
    in Fig. . Reciprocally, RUNX2 activates the PI3K/AKT pathway by regulation if
    its components, PI3K and AKT, or regulation of mTOR and RICTOR, two majors components
    of mTORC2, which phosphorylates AKT on serine 473. Upon receptor activation, the
    kinases ERK and p38 also phosphorylate and activate RUNX2. Through partnering
    with SMADs transcription factors, RUNX2, (TGFβ target gene itself) activates the
    expression of genes involved in EMT, invasion and the metastatic cascade, angiogenesis
    and bone disease. OPN: osteopontin; BSP: Bone sialoprotein; MMP: Matrix metalloproteinase;
    FAK: Focal adhesion kinase; IHH: Indian hedgehog; PTHrP: Parathyroid hormone-related
    protein; VEGF: Vascular endothelial growth factor; IL8: Interleukin-8. IL11: Interleukin-11;
    PAI-1: Plasminogen activator inhibitor-1'
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - ANGPT1
  - ANGPT2
  - ANGPT4
  - AREG
  - BDNF
  - CSF1
  - EFNA1
  - EFNA2
  - EFNA3
  - EFNA4
  - EFNA5
  - EGF
  - EREG
  - FGF1
  - FGF10
  - FGF16
  - FGF17
  - FGF18
  - FGF19
  - FGF2
  - FGF20
  - FGF21
  - FGF22
  - FGF23
  - FGF3
  - FGF4
  - FGF5
  - FGF6
  - FGF7
  - FGF8
  - FGF9
  - FLT3LG
  - HGF
  - IGF1
  - IGF2
  - INS
  - KITLG
  - NGF
  - NTF3
  - NTF4
  - PDGFA
  - PDGFB
  - PDGFC
  - PDGFD
  - PGF
  - TGFA
  - VEGFA
  - VEGFB
  - VEGFC
  - VEGFD
  - TGFB1
  - TGFB2
  - TGFB3
  - FZD4
  - NMUR1
  - LPAR3
  - LGR6
  - MRGPRX3
  - MRGPRX4
  - GPR151
  - OXER1
  - GPRC6A
  - MRGPRX1
  - VN1R17P
  - GPR166P
  - GRM1
  - GRM2
  - GRM3
  - GRM4
  - GRM5
  - GRM6
  - GRM7
  - GRM8
  - CASR
  - GABBR1
  - GABBR2
  - GPR156
  - GPR158
  - GPR179
  - GPRC5A
  - GPRC5B
  - GPRC5C
  - GPRC5D
  - PTEN
  - PIK3CA
  - PIK3CB
  - PIK3CD
  - PIK3CG
  - PIK3R3
  - PIK3R4
  - PIK3R5
  - PIK3R6
  - PIK3R1
  - PIK3R2
  - CRK
  - MAPK14
  - MAPK1
  - AIMP2
  - GRAP2
  - AHSA1
  - POLDIP2
  - MAPK11
  - MAPK12
  - MAPK13
  - AKT1
  - AKT2
  - AKT3
  - MAPKAP1
  - MTOR
  - RICTOR
  - MLST8
  - GSK3B
  - SMURF2
  - FOXO1
  - FOXO3
  - FOXO4
  - FOXO6
  - RUNX2
  - ITK
  - SLC22A3
  - MMP9
  - MMP2
  - MMP14
  - MMP13
  - IBSP
  - SPP1
  - SNAI2
  - CXCL8
  - IL11
  - IHH
  - PTHLH
  - THRSP
  - SERPINE1
  - SOX9
  - SMAD3
  - PTK2
  - Cancer
---
